Seastar Medical, operating within the rapidly growing biotechnology sector projected to reach $3879.51 billion by 2030, is at the forefront with its Selective Cytopheretic Device (SCD) aimed at treating excessive inflammation through extracorporeal therapies. Despite a significant financial downturn, with a 400% decrease in income and a substantial increase in...
Sea Star Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces receipt of U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) for use with...
![ICU: Sea Star Medical Holding [KalaGhazii]](https://s3.tradingview.com/t/tag2MbaQ_mid.png "Sea Star Medical Holding [KalaGhazii]")
